Saturday 17 October 2026
Export CHRS’s income statement to Excel — free account
Coherus Oncology, Inc.
CHRS Healthcare Biotechnology
In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.
1.00
0.07
−6.54%
Follow CHRS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 1.01 | 0.97 | 1.23 |
+8 more quarters Free account |
P/S ratio |
4.26 | 4.92 | 3.94 | 5.13 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.49) | (3.98) | (8.44) | (4.11) | |
P/B ratio |
3.56 | 2.93 | 2.73 | 2.17 | |
Price to Tangible BV |
13.68 | 6.98 | 11.26 | 4.98 | |
EV/Sales |
6.35 | 5.88 | 4.89 | 5.68 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.74) | (1.62) | (1.49) | (2.34) | |
EV/FCF |
(1.73) | (1.61) | (1.48) | (2.31) | |
Quick Ratio |
1.58 | 1.43 | 1.36 | 1.19 | |
Current Ratio |
1.77 | 1.56 | 1.47 | 1.24 | |
Net Debt/EBITDA |
2.16 | 3.68 | 3.00 | 3.57 | |
Debt/Assets |
19.48% | 13.96% | 14.34% | 7.16% | |
Debt/Equity |
0.61 | 0.47 | 0.61 | 0.42 | |
Asset Turnover |
0.16 | 0.15 | 0.12 | 0.07 | |
Operating CF/Net income |
3.01 | 1.51 | 0.52 | 1.30 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(13.92) | (16.54) | (20.40) | (19.07) | |
Research and Development Expense of Revenue |
149.87% | 175.00% | 242.97% | 235.52% | |
Selling, General and Administrative Expense of Revenue |
146.46% | 187.68% | 185.20% | 215.46% | |
Intangible Assets out of Total Assets |
0.24 | 0.17 | 0.18 | 0.10 | |
Share Based Compensation of Revenue |
18.05% | 19.37% | 21.84% | 29.29% | |
Graham Net Nets |
0.02 | 0.08 | 0.06 | 0.17 | |
Graham Number |
0.00 | 4.65 | 4.14 | 4.75 | |
Earnings Yield |
(73.57%) | 98.82% | 102.82% | 81.10% | |
Free Cash Flow Yield |
(86.26%) | (74.41%) | (83.84%) | (47.81%) | |
Revenue per Share |
0.09 | 0.09 | 0.11 | 0.10 | |
Operating CF per Share |
(0.40) | (0.42) | (0.17) | (0.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.40) | (0.42) | (0.17) | (0.40) | |
Cash per Share |
0.68 | 1.22 | 1.47 | 1.65 | |
Shareholders Equity per Share |
0.39 | 0.58 | 0.52 | 0.76 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.39 | 0.58 | 0.52 | 0.76 | |
Free Cash Flow |
(62.09) | (57.89) | (19.72) | (46.34) | |
Working Capital |
58.28 | 73.70 | 66.32 | 88.66 | |
Net Current Asset Value |
3.44 | 18.64 | 9.38 | 32.21 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
66.95 | 42.47 | 70.38 | 224.65 | |
Average Payables |
25.40 | 26.20 | 19.19 | 23.39 | |
Average Inventory |
5.09 | 4.17 | 3.69 | 24.84 | |
Average Assets |
315.32 | 318.54 | 353.44 | 510.76 | |
Average Common Equity |
90.33 | (52.42) | (35.49) | (0.10) |
Columns are period end dates